Travere Therapeutics

At a special gathering at ASN Kidney Week, we were privileged to hear Brian Parlato of The IgA Nephropathy Foundation speak about his loved ones with #IgAnephropathy. As a caregiver, Brian knows full well the emotional toll of #RareKidneyDisease, like fear of kidney failure, and knows the ins and outs of everyday caregiving -- like support in getting to doctor appointments, eating healthy, and managing the stress, fatigue and challenges of #RareDisease. This #NationalFamilyCaregiversMonth, we acknowledge the important members of the rare disease community who provide care and comfort. You truly are heroes. #InRareForLife

#HereAtTravere our team members celebrated this spooktacular Halloween season with some festive looks. Emiko’s pup really popped as a classic Coca-Cola bottle, Jerry’s son was ready pick up some candy in his Recycling truck costume, and our People Success team mean business as they protect our galaxy as MIB. Thanks again to all our team members who participated in this year’s wicked wardrobe costume contest! #TravereTherapeutics

Today we recognize National Science Technology Engineering Math (#STEM) Day. #HereAtTravere we are driven to deliver advancements in science and to develop therapies that set new standards of care for people living with rare disease. We understand the urgent need for treatment options and innovation, and we celebrate the next generation in STEM. #InRareForLife

“I’ve heard some people say that hope is not a strategy. I disagree. Sometimes hope is all you’ve got,” said Eric Dube at NephCure’s 20th annual Countdown to a Cure gala in NYC earlier this week, where he and others were honored for their impact in #RareKidneyDisease. The moving event brings together donors, physicians, patient families, industry supporters, and friends to support NephCure’s mission. Together with NephCure, we will continue to work to translate hope into reality. #InRareForLife

Today we reported our third quarter 2024 financial results. Press release: https://bit.ly/3Al4n3U

We’d like to extend a huge thank you to the American Society of Nephrology and to everyone who joined us at #ASN24 #KidneyWk. It was a pleasure coming together and sharing our clinical data and research in #IgAN and #FSGS. Thank you to all those who contributed to another thought-provoking and inspiring meeting on advances in #RareKidneyDisease (RKD).

This week we presented new data reinforcing the clinical benefit of our medicine for #IgAN and a late-breaking presentation in #FSGS at ASN #KidneyWk. Press release: https://lnkd.in/g9ZDFW4K

We look forward to sharing our latest research in #RareKidneyDisease, including #IgAnephropathy and #FSGS at #KidneyWk 2024. Our presentations will highlight new data from the SPARTAN and SPARTACUS Studies, provide an analysis from the PROTECT Study examining the effect of sparsentan treatment regardless of participants’ baseline proteinuria, as well as new data from the PROTECT OLE and real-world clinical experience on combination treatment in #IgAN. Check out all our presentations below. #InRareForLife

We’ve arrived and we didn’t have to travel far! This week we are lucky to have the American Society of Nephrology #ASN24 #KidneyWk back in San Diego. We look forward to presenting and engaging with the dedicated specialists and experts in the nephrology community in the days ahead.

In this episode of the RKD podcast, hear Drs. Luis Vélez and Jessica Coleman discuss the perception and management of #IgAnephropathy. New research and registry data, particularly from the UK RaDaR Registry, has demonstrated that IgA nephropathy can progress to end-stage kidney disease and affects younger patients more severely than initially thought. These insights suggest consideration of more aggressive treatment strategies.?? Listen to the full episode for more insights: https://bit.ly/407YTnF